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USE OF PLASMA EXCHANGE FOR THE TREATMENT OF HEPATIC VENO-
OCCLUSIVE DISEASE (VOD)/SINUSOIDAL OBSTRUCTION SYNDROME
(SOS) AFTER REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM
CELL TRANSPLANTATION
Garcı´a Sepu´lveda, C.A., Ovilla Martı´nez, R. Hospital Angeles Lomas,
Huixquilucan, Mexico.
Hepatic veno-occlusive disease/sinusoidal obstructive syndrome
(VOD/SOS) is a severe regimen-related complication of allogeneic
stem cell transplantation that occurs in 10% to 60% of recipients
and is characterized by a high mortality. Until recently, the ther-
apeutic management of hepatic VOD/SOS has relied on the use of
a wide spectrum of pharmacologic agents which include: heparin,
ursodiol, prostaglandins and pentoxifylline, albeit with limited suc-
cess. In recent years the description of promising results regarding
the use of deﬁbrotide for the prevention and management of
moderate to severe hepatic VOD/SOS has been shown. However,
the use of this pharmacologic agent is still under clinical investi-
gation and not available for patients living outside of the trial-
sponsoring countries. Here we describe the successful treatment of
a case of severe hepatic VOD/SOS by means of plasma exchange,
a procedure that is thought to alleviate liver failure by eliminating
inﬂammatory cytokines and pro-coagulant substances circulating
in the peripheral blood of affected patients. The patient was a 53
year old male undergoing allogeneic haematopoietic stem cell
transplantation from a related, HLA-matched (10/10) donor due to
chronic prolymphocytic leukaemia. The patient was subjected to a
reduced intensity conditioning (RIC) regimen (TBI  ﬂudara-
bine  ATG) and received methylprednisolone alone as GvHD
prophylaxis. The patient developed clinical hepatic VOD/SOS on
day 7 characterized by increased total serum bilirubin levels at
the expense of direct bilirubin (reaching 25 mg/dL in less than 36
hours), jaundice, ascites, upper-quadrant pain, hepatomegaly, re-
spiratory distress and hepatic encephalopathy, soon after the pa-
tient developed renal failure. The patient was subjected to three
3-liter plasma exchange sessions on separate days starting on day
8. On day 10, alanine amino transferase, lactic dehydrogenase
and bilirubin levels achieved their maximum (1306 IU/L, 3597
IU/L and 35 mg/dL, respectively). By day 15 the bilirubins and
most liver enzymes had regained their normal levels. The patient
subsequently developed progressive multifocal leukoencephalopa-
thy that culminated in the patient’s death on day49. Our analysis
allows us to conclude that hepatic VOD/SOS is an important
complication of reduced intensity conditioning regimens that can
be managed and overcome by an easily accessible therapeutical
approach such as plasma exchange.
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ISOLATED EXTRAMEDULLARY RELAPSE PRESENTING AS GRANULO-
CYTIC SARCOMA AFTER BONE MARROW TRANSPLANTATION: A SINGLE
CENTER EXPERIENCE
Ganguly, S., Joseph, R., Delva, D.-L., Skikne, B. University of Kansas
Medical Center, Kansas City, KS.
Background: Granulocytic sarcomas are rare extramedullary
solid aggregates of malignant myeloid precursor cells. Granulo-
cytic sarcoma after bone marrow transplantation (BMT) is rare.
We found 2 cases of post-transplant granulocytic sarcoma out of
121 patients (1.7%) who underwent allogeneic bone marrow trans-
plantation for acute myeloid leukemia (AML) at our institution
between 1977 and 2005.Case 1: A 45-year-old male was diagnosed
with AML-M1 in July 2002. He received haplo-identical allogeneic
bone marrow transplantation from his son. He suffered minimal
chronic graft versus host disease (GVHD). Two years after the
bone marrow transplant, the patient presented with features of
compressive myelopathy secondary to a large mid-thoracic granu-
locytic sarcoma. He was treated with surgical decompression and
local radiation. Bone marrow done concurrently showed morpho-
logical remission with 100% donor chimerism. He was subse-
quently treated with a mini cord transplant, but ultimately died due
to transplant related complications. Case 2: A 23-year-old male
was diagnosed with AML-M4 and multiple cytogenetic abnormal-
ities in July 2004. He underwent matched unrelated bone marrow
transplantation in January 2005. He was on maintenance immu-
nosuppressive treatment for chronic GVHD. In July 2005, he
presented with features of cauda-equina syndrome secondary to a
pre-sacral granulocytic sarcoma. He was treated with local radia-
tion. Bone marrow done concurrently showed morphological and
cytogenetic remission with 100% donor chimerism. Two months
later, due to progressive disease and poor performance status,
patient and family decided against further chemotherapy. Discus-
sion: Post transplant granulocytic sarcoma is rare (1.7%). Failure
of extramedullary immune surveillance may explain occurrence of
such tumors when bone marrow is still free from relapse. Most of
the extramedullary relapses have been noted in recipients of allo-
geneic BMT with minimal GVHD. Our ﬁrst patient did not have
any evidence of GVHD and developed extramedullary relapse after
two years of receiving haplo-identical bone marrow transplanta-
tion. In contrast, the second patient developed GVHD and devel-
oped granulocytic sarcoma relatively early in the post transplant
period. Immune evasion might have played a role in the pathogen-
esis of the tumor in our second patient. Both of them faired poorly
underscoring the fact that post transplant granulocytic sarcoma
carries a sinister prognosis.
GVH/GVL
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THE ROLE OF MEMBRANE BOUND TNF IN GVHD AND GVT ACTIVITY BY
ALLOREACTIVE T CELLS
Borsotti, C., Keating, A., Kochman, A., Suh, D., Smith, O.M.,
Kim, T.D., Alpdogan, O., van den Brink, M.R. Department of Medicine
and Immunology, Memorial Sloan-Kettering Cancer Center, New York,
NY.
Tumor necrosis factor (TNF) is a member of the TNF super-
family which an important role in pathophysiology of GVHD. We
have previously shown that donor T cell-derived TNF is required
for GVHD and GVT activity. However, TNF can be expressed as
a membrane bound (memTNF) or soluble (solTNF) form after
cleavage by the TNF converting enzyme (TACE). To distinguish
the relative contribution of memTNF vs solTNF in GVHD and
GVT, we used memTNFdelta/delta with a combined deletion of
wt TNF and knock-in of a mutated TNF, which is resistant to
TACE-mediated cleavage. We found no difference in GVHD
between wt or memTNF T cells (B6 into C3FeB6F1/J). However,
recipients of puriﬁed memTNF CD4 T cells had signiﬁcantly
improved survival as compared to recipients of wt CD4 T cells
(80% vs 10% on day 80 after BMT, P  .0001). Absolute numbers
and expression of activation markers (CD25, CD44 and CD62L)
on alloreactive splenic donor CD4 T cells was not signiﬁcantly
different between the two groups on days 7, 14, 21 and 28. We did
not detect any difference in serum IFN-gamma at various time
points after transplant between recipients of memTNF vs wt
CD4 T cells. Thymic GVHD as assessed by analysis of overall
thymic cellularity and absolute numbers of CD4/CD8 double
positive (DP) cells was less in the memTNF group on days 21 after
BMT. Hematopoietic recovery after transplant did not differ be-
tween recipients of memTNF vs wt CD4 T cells. In a GVHD/
GVT model (B6 into B6D2F1 with P815) we found that survival of
recipients of memTNF T cells was signiﬁcantly improved as com-
pared to recipients of BM only or wt T cells, demonstrating that
GVT activity was not impaired in recipients of memTNF T cells.
On day 80 after transplant survival of recipients of memTNF vs wt
T cells was: 50% and 20% (P  .0051). Taken together these
results show that elimination of donor T cell-derived soluble TNF
signiﬁcantly decreases GVHD while the membrane bound form
seems to be sufﬁcient for GVT activity. Targeting the cleavage of
membrane bound TNF by TACE may be a promising strategy for
the treatment of GVHD.
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